Pliant Therapeutics, Inc.
Clinical trials sponsored by Pliant Therapeutics, Inc., explained in plain language.
-
New drug shows promise in shrinking lung scars in IPF patients
Disease control CompletedThis study tested a new drug called PLN-74809 in 10 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. The goal was to see if the drug could reduce scarring in the lungs over 12 weeks. Participants took either the drug or a placebo, and doctors …
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
New drug shows promise for rare liver disease in early trial
Disease control CompletedThis study tested a new medicine called PLN-74809 in 121 adults with primary sclerosing cholangitis (PSC) and suspected liver scarring. The main goal was to check if the drug is safe and tolerable at different doses compared to a placebo. Researchers also measured how much of the…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:21 UTC